Pédiatrie 1, CHU de Hautepierre, Avenue Moliere, Strasbourg, France.
J Ren Nutr. 2011 Jan;21(1):43-6. doi: 10.1053/j.jrn.2010.10.022.
Despite major advances in the understanding and management of uremic growth failure, 35% to 50% of children with chronic kidney disease still grow up to become adults of small stature. The final adult height achieved is correlated with the height deficit recorded at the time of kidney transplantation. A degree of catch-up growth does occur after kidney transplantation in childhood, but it is often limited. Growth retardation in children with chronic kidney disease causes significant difficulties in their daily lives, often limiting psychosocial integration. Additionally, growth retardation is associated with a greater number of hospital admissions and an increased risk of mortality. Growth failure is the common endpoint of a variety of pathologies, including growth hormone resistance. In children on chronic dialysis, linear growth may be improved by ensuring that optimal clinical care is provided. This includes maximizing nutritional support (e.g., tube feeding in cases of anorexia) so as to prevent malnutrition. Further management options include the administration of recombinant human growth hormone (rhGH) treatment and the use of more frequent and intensive dialysis sessions, such as daily on-line hemodiafiltration, which combines increased dialysis convective flow with ultrapure dialysate, to limit cachexia.
尽管在理解和治疗尿毒症性生长障碍方面取得了重大进展,但仍有 35%至 50%的慢性肾脏病儿童最终身高矮小。最终成年身高与接受肾移植时记录的身高缺陷相关。在儿童期接受肾移植后,确实会出现一定程度的追赶性生长,但往往有限。慢性肾脏病儿童的生长迟缓会给他们的日常生活带来严重困难,经常限制他们的社会心理融合。此外,生长迟缓与更多的住院和更高的死亡率有关。生长失败是多种病理的共同终点,包括生长激素抵抗。在慢性透析的儿童中,通过确保提供最佳的临床护理,线性生长可能会得到改善。这包括最大限度地提供营养支持(例如,在厌食症的情况下进行管饲),以防止营养不良。进一步的管理选择包括给予重组人生长激素(rhGH)治疗和更频繁、更密集的透析治疗,如每日在线血液透析滤过,该治疗将增加的透析对流与超纯透析液结合起来,以限制恶病质。